证券代码：002141 证券简称：贤丰控股 公告编号：2023-035 贤丰控股股份有限公司 独立董事候选人声明与承诺 声明人肖世练作为贤丰控股股份有限公司第八届董事会独立董事候选人，已 充分了解并同意由提名人贤丰控股股份有限公司董事会提名为贤丰控股股份有 限公司（以下简称"该公司"）第八届董事会独立董事候选人。现公开声明和保 证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行 政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任 职资格及独立性的要求，具体声明并承诺如下： 一、本人已经通过贤丰控股股份有限公司第七届董事会提名委员会或者独立 董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑是 □否 如否，请详细说明：____________________________ 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 ☑是 □否 如否，请详细说明：____________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独 ...

证券代码：002141 证券简称：贤丰控股 公告编号：2023-034 贤丰控股股份有限公司 独立董事候选人声明与承诺 声明人梁融作为贤丰控股股份有限公司第八届董事会独立董事候选人，已充 分了解并同意由提名人贤丰控股股份有限公司董事会提名为贤丰控股股份有限 公司（以下简称"该公司"）第八届董事会独立董事候选人。现公开声明和保证， 本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行政法 规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资 格及独立性的要求，具体声明并承诺如下： 一、本人已经通过贤丰控股股份有限公司第七届董事会提名委员会或者独立 董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑是 □否 如否，请详细说明：____________________________ 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 ☑是 □否 如否，请详细说明：____________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立 ...

证券代码：002141 证券简称：贤丰控股 公告编号：2023-038 贤丰控股股份有限公司 独立董事提名人声明与承诺 提名人贤丰控股股份有限公司董事会现就提名肖世练为贤丰控股股份有限 公司第八届董事会独立董事候选人发表公开声明。被提名人已书面同意作为贤丰 控股股份有限公司第八届董事会独立董事候选人（参见该独立董事候选人声明）。 本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人 任职资格及独立性的要求，具体声明并承诺如下事项： ☑ 是 □ 否 如否，请详细说明：____________________________ 四、被提名人符合公司章程规定的独立董事任职条件。 ☑ 是 □ 否 一、被提名人已经通过贤丰控股股份有限公司第七届董事会提名委员会或者 独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其他可能影 响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：____________________________ 二、 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥53,349,196.03, a decrease of 91.09% compared to ¥598,439,372.45 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was -¥20,783,669.20, representing a decline of 188.87% from a profit of ¥23,387,289.92 in the previous year[19]. - The net cash flow from operating activities was -¥38,296,134.46, which is a 44.02% increase in cash outflow compared to -¥26,590,990.28 in the same period last year[19]. - The basic earnings per share were -¥0.0183, down 188.83% from ¥0.0206 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was -¥33,923,806.97, a slight increase in loss of 1.83% compared to -¥33,314,762.23 in the previous year[19]. - The company reported a significant shift in its revenue structure, with biological products accounting for 81.03% of total revenue at ¥43,227,119.62, up 48.26% year-on-year[37]. - The company reported a net loss of CNY 206,982,170.38 as of June 30, 2023, compared to a loss of CNY 186,188,290.85 at the beginning of the year[121]. - The total comprehensive income for the first half of 2023 was -7,270,773.24 CNY, compared to 96,785,532.94 CNY in the same period of 2022, indicating a substantial decline in overall financial performance[134]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,296,395,708.57, a decrease of 3.49% from ¥1,343,332,102.28 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were ¥1,136,658,701.30, down 0.82% from ¥1,146,062,191.42 at the end of the previous year[19]. - Cash and cash equivalents decreased to ¥77,721,087.28, representing 6.00% of total assets, down from 16.53% last year, a decrease of 10.53%[42]. - Total liabilities decreased from CNY 124,403,793.49 to CNY 89,485,459.74, a reduction of approximately 28.1%[121]. - The company's equity attributable to shareholders decreased from CNY 1,146,062,191.42 to CNY 1,136,658,701.30, a decline of about 0.8%[121]. Research and Development - The company has increased its R&D personnel significantly, particularly in cutting-edge technology and product development, including the recruitment of a chief scientist[30]. - Research and development expenses decreased by 69.99% to ¥7,403,817.69 from ¥24,673,458.50 in the previous year[35]. - The company is investing in new technologies and product development to comply with evolving regulatory standards in the veterinary biological products sector[59]. Market and Competition - The company’s veterinary vaccine business is closely tied to the pig farming industry, which has faced a continuous decline in pig prices for 8 months, leading to intensified price competition in the veterinary vaccine sector[27]. - The company reported a decrease in gross profit margins due to the ongoing downturn in the pig farming industry and increased competition[27]. - The veterinary biological products industry is experiencing high competition, and the company is focusing on enhancing its market risk management strategies[58]. Environmental Responsibility - The company has established an emergency response plan for environmental incidents, valid from July 2022 to July 2025[69]. - The company has implemented low-nitrogen burners in its gas boiler to reduce nitrogen oxide emissions[69]. - The company has a commitment to corporate social responsibility, focusing on environmental protection and stakeholder rights[70]. Corporate Governance - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[3]. - The company has maintained a good relationship with suppliers and actively works on customer satisfaction improvement[71]. - There were no significant lawsuits or arbitration matters during the reporting period[80]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 44,802[107]. - Guangdong Xianfeng Holdings Co., Ltd. holds 26.03% of the shares, totaling 295,358,647 ordinary shares, which are pledged[107]. - The company has not issued any new shares or conducted any share repurchase during the reporting period[105]. Financial Management - The total amount of entrusted financial management is 81 million RMB, with an unexpired balance of 54.06 million RMB[96]. - The company has no overdue amounts for entrusted financial management products, indicating a strong liquidity position[96]. - The company has not reported any high-risk entrusted financial management situations, indicating a cautious investment approach[98]. Accounting Policies - The financial statements are prepared based on the actual transactions and events in accordance with the accounting standards issued by the Ministry of Finance[163]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[164]. - The accounting policies and estimates are tailored to the characteristics of the company's main business of animal health vaccines[165].

贤丰控股股份有限公司 独立董事对第七届董事会第二十六次会议相关事项的 专项说明和独立意见 根据《上市公司独立董事规则》、《深圳证券交易所股票上市规则》以及《公 司章程》、《董事会议事规则》、《独立董事工作制度》等有关规定的要求，作 为贤丰控股股份有限公司（以下简称"公司"）的独立董事，我们对第七届董事 会第二十六次会议相关事项进行了认真审议，并基于独立判断的立场发表如下独 立意见： （以下无正文） （本页无正文，为贤丰控股股份有限公司独立董事对第七届董事会第二十六次会 议相关事项的专项说明和独立意见的签字页） 独立董事： 王铁林 邓延昌 梁融 一、关于公司对外担保情况和控股股东及其他关联方占用公司资金情况的 独立意见和专项说明 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》（证监会公告〔2022〕26 号）等规定，作为公司的独立董事，对报告期（2023 年 1 月 1 日至 2023 年 6 月 30 日）公司的对外担保情况和控股股东及其他关联 方占用资金情况进行核查，经核查： 1. 公司严格遵循《公司法》、《证券法》、《关于规范上市公司对外担保 行为的通知》等法律法规和《公司章 ...

证券代码：002141 证券简称：贤丰控股 公告编号：2023-025 贤丰控股股份有限公司 第七届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1. 贤丰控股股份有限公司（以下简称"公司"）第七届董事会第二十六次会 议通知于 2023 年 8 月 6 日以电话、邮件等方式发出。 3. 会议应参与表决董事 7 人，实际参与表决董事 7 人（其中：以通讯表决 方式出席会议的董事 3 人，分别为独立董事王铁林、邓延昌、梁融）。 4. 会议由公司董事长韩桃子女士主持，公司高级管理人员列席了会议。 5. 本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 二、董事会会议审议情况 1.审议通过《2023 年半年度报告》及其摘要 表决结果：以 7 票赞成，0 票弃权，0 票反对的表决结果，通过本议案。 具体内容详见与本公告同日刊载于巨潮资讯网（www.cninfo.com.cn）上的 相关公告。 三、备查文件 1. 经与会董事签字并加盖董事会印章的董事会决议。 特此公告。 1 2 ...

贤丰控股股份有限公司2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：贤丰控股股份有限公司 非经营性资金占用 资金占用方名称 占用方与上市公司的关联关 系 上市公司核算 的会计科目 2023年期初占用资 金余额 2023年半年度占用 累计发生金额（不 含利息） 2023年半年度占用 资金的利息(如有) 2023年度偿还累计 发生金额 2023年期末占 用资金余额 占用形成原因 占用性质 现大股东及其附属企业 小计 - - - - 前大股东及其附属企业 小计 - - - - 总计 - - - - 其它关联资金往来 资金往来方名称 往来方与上市公司的关联关 系 上市公司核算 的会计科目 2023年期初往来资 金余额 2023年半年度往来 累计发生金额（不 含利息） 2023年半年度往来 资金的利息(如有) 2023年半年度偿还 累计发生金额 2023年半年度 期末往来资金 余额 往来形成原因 往来性质 大股东及其附属企业 广州丰盈基金管理有限公司 联营企业并同一控制股东 预付账款 -3.40 215.71 212.31 - 基金管理费 经营性往来 上市公司的子公司及其附属企业 深圳市深江泰贸 ...

证券代码：002141 证券简称：贤丰控股 公告编号：2023-026 贤丰控股股份有限公司 第七届监事会第十八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1. 贤丰控股股份有限公司（以下简称"公司"）第七届监事会第十八次会议 的会议通知已于 2023 年 8 月 6 日以电话通知、电子邮件等形式送达全体监 事。 2. 会议于 2023 年 8 月 11 日在公司会议室以现场与通讯表决相结合的方式 召开。 3. 会议应参与表决监事 3 人，实际参与表决监事 3 人（其中：以通讯表决 方式出席会议的监事 1 人，为黎展鹏）。 4. 会议由监事会主席王广旭先生主持，公司高级管理人员列席了会议。 5. 本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 二、监事会会议审议情况 监事会对公司 2023 年半年度报告进行了全面了解和审核，监事会对公司 2023 年半年度报告有关事项的审核意见如下： (1)编制和审议情况 公司 2023 年半年度报告的编制和审议程序符合法律、法规、《公司章程 ...

证券代码：002141 证券简称：贤丰控股 公告编号：2023-029 贤丰控股股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 财政部于 2022 年 11 月 30 日发布了《企业会计准则解释第 16 号》（财会 〔2022〕31 号）（以下简称"解释第 16 号"）。根据解释第 16 号规定，贤丰控 股股份有限公司（以下简称"公司"）需按照解释第 16 号的相应要求进行相应 的变更，对公司财务状况、经营成果和现金流量不会产生重大影响。具体情况如 下： 一、本次会计政策变更概述 （一）会计政策变更原因和变更日期 财政部于 2022 年 11 月 30 日公布了《企业会计准则解释第 16 号》（财 会〔2022〕31 号，以下简称"解释第 16 号"）。解释第 16 号规定"关于单项 交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理"内 容自 2023 年 1 月 1 日起施行。 对于在首次施行本解释的财务报表列报最早期间的期初至本解释施行日之 间发生的适用本解释的单项交易，企业应当按照本解释的规定进行调整 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥29,298,048.67, a decrease of 89.32% compared to ¥274,449,534.28 in the same period last year[3] - The net profit attributable to shareholders for Q1 2023 was ¥4,774,983.01, down 72.88% from ¥17,608,180.89 year-on-year[3] - Basic and diluted earnings per share for Q1 2023 were both ¥0.0042, representing a decrease of 72.90% from ¥0.0155 in the same period last year[3] - The company reported a comprehensive income total of ¥1,154,797.96, a decrease of 91.94% from ¥14,330,146.74 year-over-year[17] - Net profit for Q1 2023 was ¥5,227,017.88, a decrease of 66.47% from ¥15,563,776.00 in Q1 2022[17] Cash Flow - The net cash flow from operating activities was -¥6,182,905.64, a decline of 183.72% compared to ¥7,385,550.42 in the previous year[3] - Total cash inflow from operating activities was 36,128,256.65, while cash outflow was 42,311,162.29, resulting in a net cash outflow of 6,182,905.64[20] - Cash flow from investing activities showed a net outflow of -¥59,325,858.17, compared to a net inflow of 35,046,952.79 in the previous year[20] - The net cash flow from financing activities was -¥1,837,553.67, compared to -¥16,645,350.99 in Q1 2022[20] - The net increase in cash and cash equivalents for the quarter was -67,588,548.37, compared to an increase of 25,819,380.14 in the previous year[20] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,327,981,593.12, a decrease of 1.14% from ¥1,343,332,102.28 at the end of the previous year[3] - The total current assets as of March 31, 2023, amount to 749,009,185.54 CNY, a decrease from 761,626,922.95 CNY at the beginning of the year[13] - The total current liabilities as of March 31, 2023, are 83,168,157.40 CNY, down from 98,238,788.49 CNY at the beginning of the year[14] - The company's total liabilities decreased to ¥107,898,486.37 from ¥124,403,793.49, reflecting a reduction of 13.23%[15] - The total equity attributable to shareholders increased slightly to ¥1,146,764,954.51 from ¥1,146,062,191.42, indicating a marginal growth of 0.06%[15] Investment and Income - The company reported a significant increase in investment income of 171.15%, amounting to ¥1,253,041.70 compared to a loss of -¥1,761,248.19 in the previous year[7] - The fair value change income was ¥6,458,780.60, a substantial increase of 80,529.33% compared to ¥8,010.46 in the same period last year[8] - Cash received from sales of goods and services was ¥31,005,888.94, down 89.85% from ¥306,099,180.69 in the previous year[19] - The company received tax refunds amounting to 9,094,353.25 during the quarter[20] - The company reported cash received from other operating activities totaling 5,122,367.71[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,592[9] - Guangdong Xianfeng Holdings Co., Ltd. holds 26.03% of shares, amounting to 295,358,647 shares, with 292,200,000 shares pledged[9] - Xianfeng Holdings Group Co., Ltd. owns 14.03% of shares, totaling 159,152,000 shares, with 114,000,000 shares pledged[9] Project Announcements - The company announced the approval of the lithium carbonate extraction project pilot engineering on January 4, 2023[11] - The company has subscribed to private equity fund shares as announced on March 17, 2023[11]